Innovations in the pharmaceutical sector necessitate the conduct of clinical trials for marketing the products. These trials form the basis for applications purposed at safeguarding pioneering therapeutic applications of potential products – such as preferred formulations, combinations, dosages, and new medical uses. However, patentability of these inventions may be negatively affected by disclosures related to such clinical trials.
A closer look and comparison of recent decisions on patents in the U.S. and Europe yields vital guidance for corporations grappling with the impact of disclosures in clinical trials on product patentability. Areas of key concern include dealing with public use issues and handling prior art documents, especially in these commercially essential jurisdictions.
Lawyers at Finnegan highlight these challenges and share insights on maintaining a balance between the necessity of conducting clinical trials and preserving the patentability of substances within these clinical trials. Their detailed analysis can provide a clearer understanding of best practices in this nuanced field, helping companies navigate the complex intersection of clinical trials and patent law in these crucial markets. For an in-depth review of the subject and its potential implications, you can visit the full analysis here.